• 1
    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007; 25: 884-896.
  • 2
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
  • 3
    O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101: 3597-3605.
  • 4
    O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003; 9: 5465-5476.
  • 5
    Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337.
  • 6
    Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
  • 7
    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-2524.
  • 8
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
  • 9
    Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncology. 2009; 10: 757-763.
  • 10
    Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978; 19: 579-592.
  • 11
    Saitoh H. Distant metastasis of renal adenocarcinoma. Cancer. 1981; 48: 1487-1491.
  • 12
    Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998; 83: 2548-2553.
  • 13
    Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998; 16: 2261-2266.
  • 14
    Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996; 47: 187-193.
  • 15
    Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997; 37: 753-759.
  • 16
    Chang EL, Selek U, Hassenbusch SJ 3rd, et al. Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery. 2005; 56: 936-945; discussion 936-945.
  • 17
    Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008; 113: 2539-2548.
  • 18
    SUTENT (sunitinib malate) prescribing information. Available at: Accessed November 16, 2009.
  • 19
    Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007; 18: 1282-1283.
  • 20
    Negrier S. Case Report 3. Sunitinib malate in patients with cerebellar metastases. Eur J Cancer. 2007; 5(suppl): 32-34.
  • 21
    Helgason HH, Mallo HA, Droogendijk H, Haanen JG, van der Veldt AA, van den Eertwegh AJ, Boven E. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008; 26: 152-154.
  • 22
    Patyna S, Peng J. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer. 2006; 4: 21.
  • 23
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
  • 24
    Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454-463.
  • 25
    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296.
  • 26
    Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol. 2007; 25(suppl 18s). Abstract 15506.
  • 27
    Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010; 21: 1027-1031.
  • 28
    Sunitinib in treating patients with kidney cancer that has spread to the brain, 12/09 update. Available at:
  • 29
    Novello S, Abrey LE, Grossi F, Camps C, Mazieres J, Selaru P, Patyna S, Torigoe Y, Chao R, Scagliotti G. Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: a phase II trial. J Clin Oncol. 2009; 27(suppl 15s). Abstract 8077.
  • 30
    Wuthrick EJ, Curran WJ, Werner-Wasik M, et al. A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. J Clin Oncol. 2008; 26 ( May 20 suppl). Abstract 2053.